- Home
- HKPD vs LPCN Comparison
HKPD vs LPCN Comparison
Compare HKPD & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- LPCN
- Stock Information
- Founded
- HKPD 2016
- LPCN 1997
- Country
- HKPD Hong Kong
- LPCN United States
- Employees
- HKPD N/A
- LPCN N/A
- Industry
- HKPD Other Pharmaceuticals
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- HKPD Health Care
- LPCN Health Care
- Exchange
- HKPD Nasdaq
- LPCN Nasdaq
- Market Cap
- HKPD 15.9M
- LPCN 16.4M
- IPO Year
- HKPD 2025
- LPCN N/A
- Fundamental
- Price
- HKPD $1.06
- LPCN $2.83
- Analyst Decision
- HKPD
- LPCN Strong Buy
- Analyst Count
- HKPD 0
- LPCN 1
- Target Price
- HKPD N/A
- LPCN $10.00
- AVG Volume (30 Days)
- HKPD 120.0K
- LPCN 13.0K
- Earning Date
- HKPD 01-01-0001
- LPCN 05-08-2025
- Dividend Yield
- HKPD N/A
- LPCN N/A
- EPS Growth
- HKPD N/A
- LPCN N/A
- EPS
- HKPD 0.21
- LPCN N/A
- Revenue
- HKPD $20,770,344.00
- LPCN $11,198,144.00
- Revenue This Year
- HKPD N/A
- LPCN N/A
- Revenue Next Year
- HKPD N/A
- LPCN N/A
- P/E Ratio
- HKPD $5.07
- LPCN $1,864.17
- Revenue Growth
- HKPD 32.91
- LPCN N/A
- 52 Week Low
- HKPD $1.00
- LPCN $2.75
- 52 Week High
- HKPD $3.79
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- HKPD N/A
- LPCN 33.48
- Support Level
- HKPD N/A
- LPCN $2.75
- Resistance Level
- HKPD N/A
- LPCN $3.57
- Average True Range (ATR)
- HKPD 0.00
- LPCN 0.27
- MACD
- HKPD 0.00
- LPCN -0.05
- Stochastic Oscillator
- HKPD 0.00
- LPCN 8.16
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.